<?xml version='1.0' encoding='utf-8'?>
<document id="32129697"><sentence text="Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor."><entity charOffset="118-127" id="DDI-PubMed.32129697.s1.e0" text="rucaparib" /></sentence><sentence text="1" /><sentence text=" The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was characterised in vitro" /><sentence text="2" /><sentence text=" Rucaparib showed moderate cellular permeability, moderate human plasma protein binding (70" /><sentence text="2%), and slow metabolism in human liver microsomes (HLMs)" /><sentence text=" In HLMs, cytochrome P450 (CYP) 1A2 and CYP3A contributed to the metabolism of rucaparib to its major metabolite M324 with estimated fractions of metabolism catalysed by CYP (fm,CYP) of 0" /><sentence text="27 and 0" /><sentence text="64, respectively" /><sentence text=" Rucaparib reversibly inhibited CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3As (IC50, 3" /><sentence text="55, 12" /><sentence text="9, 5" /><sentence text="42, 41" /><sentence text="6, and 17" /><sentence text="2-22" /><sentence text="9 µM [2 substrates], respectively), but not CYP2B6 or CYP2C8 (&gt;190 µM)" /><sentence text=" No time-dependent inhibition of any CYP was observed" /><sentence text=" In cultured human hepatocytes, rucaparib showed concentration-dependent induction of CYP1A2 mRNA and downregulation of CYP3A4 and CYP2B6 mRNA" /><sentence text=" In transfected cells expressing drug transporters, rucaparib was a substrate for P-gp and BCRP, but not for OATP1B1, OATP1B3, OAT1, OAT3, or OCT2" /><sentence text=" Rucaparib inhibited P-gp and BCRP (IC50, 169 and 55 µM, respectively) and slightly inhibited OATP1B1, OATP1B3, OAT1, and OAT3 (66%, 58%, 58%, and 42% inhibition, respectively) at 300 µM" /><sentence text=" Rucaparib inhibited OCT1, OCT2, MATE1, and MATE2-K (IC50, 4" /><sentence text="3, 31, 0" /><sentence text="63, and 0" /><sentence text="19 μM, respectively)" /><sentence text="3" /><sentence text=" DDI risk assessment using static models suggested potential CYP-related DDIs, with rucaparib as a perpetrator"><entity charOffset="84-93" id="DDI-PubMed.32129697.s26.e0" text="rucaparib" /></sentence><sentence text=" Caution is advised when co-administering rucaparib with sensitive substrates of MATEs, OCT1, and OCT2"><entity charOffset="42-51" id="DDI-PubMed.32129697.s27.e0" text="rucaparib" /></sentence><sentence text="" /></document>